Expertise in
15
conditions

Dr. Wenqing Zhang

Hematology | Hematology Oncology | Oncology
Florida Cancer Specialists And Research Institute, LLC
521 N Lecanto Hwy, Florida Cancer Specialists Pl, 
Lecanto, FL 
 (1436.2 mi)
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
Florida Cancer Specialists And Research Institute, LLC
521 N Lecanto Hwy, Florida Cancer Specialists Pl, 
Lecanto, FL 
 (1436.2 mi)
OverviewInsuranceLocationsClinical Research

Overview

Wenqing Zhang is a Hematologist and a Hematologist Oncology provider in Lecanto, Florida. Dr. Zhang is highly rated in 15 conditions, according to our data. His top areas of expertise are Iron Deficiency Anemia, Lung Cancer, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Zhang is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Oncology
Licenses
Internal Medicine in TN
Hospital Affiliations
Hca Florida Citrus Hospital
Tampa General Hospital Crystal River
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Health Options
  •  Oscar
  •  Florida Blue

Locations

FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
521 N Lecanto Hwy, Florida Cancer Specialists Pl, Lecanto, FL 34461

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
View 6 Less Clinical Trials

4 Total Publications

Degradation of polycyclic aromatic hydrocarbons in aquatic environments by a symbiotic system consisting of algae and bacteria: green and sustainable technology.
Degradation of polycyclic aromatic hydrocarbons in aquatic environments by a symbiotic system consisting of algae and bacteria: green and sustainable technology.
Journal: Archives of microbiology
Published: September 05, 2023
Similar Doctors
Expertise in
25
conditions
Dr. Eric Padron
Oncology | Hematology | Hematology Oncology
Expertise in
25
conditions
Dr. Eric Padron
Oncology | Hematology | Hematology Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (55.8 mi)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Padron is an Oncologist and a Hematologist in Tampa, Florida. Dr. Padron is highly rated in 25 conditions, according to our data. His top areas of expertise are Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Padron is currently accepting new patients.

Expertise in
32
conditions
Dr. Jeffrey Lancet
Hematology Oncology | Hematology | Oncology
Expertise in
32
conditions
Dr. Jeffrey Lancet
Hematology Oncology | Hematology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (55.8 mi)
888-860-2778
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Lancet is a Hematologist Oncology specialist and a Hematologist in Tampa, Florida. Dr. Lancet is highly rated in 32 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
29
conditions
Dr. Andrew Brohl
Hematology Oncology | Oncology | Hematology
Expertise in
29
conditions
Dr. Andrew Brohl
Hematology Oncology | Oncology | Hematology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (55.8 mi)
888-860-2778
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Brohl is a Hematologist Oncology specialist and an Oncologist in Tampa, Florida. Dr. Brohl is highly rated in 29 conditions, according to our data. His top areas of expertise are Merkel Cell Carcinoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Melanoma.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile